Learn how menopause VMS stem from the brain, last years, affect heart risk, and when hormone therapy is considered safe.

Discover how community pharmacists can spot menopause beyond vasomotor symptoms, avoid HRT mix-up myths, and collaborate on safe, updated treatments.

How pharmacists can spot menopause beyond hot flashes, update hormone therapy knowledge, and collaborate on dosing amid estrogen patch shortages.

New NK3 receptor blockers target hypothalamic ‘KNDy’ neurons, offering new drug targets in guideline-recognized therapy for VMS and hot flashes.

New NK3 receptor blockers target hypothalamic “KNDy” neurons, easing menopause vasomotor symptoms without hormones and gaining top guideline support.

Phase 3 SKYLIGHT and OASIS trials show rapid, week 1 relief of menopausal hot flashes, with key safety findings and mixed sleep benefits.

Phase 3 SKYLIGHT and OASIS trials show rapid relief of menopausal hot flashes—often within one week—plus strong safety data, with sleep outcomes under close study.

Learn how new nonhormonal menopause drugs ease vasomotor symptoms and improve sleep, and who benefits—plus key adverse effects and liver monitoring.

Learn how pharmacists open symptom-first menopause talks, weigh hormonal vs nonhormonal options, and counter social media myths.

See how a team-based menopause clinic pairs pharmacists, gynecologists, and pelvic floor therapy to streamline care, screening, and symptom relief.

The panelists examined the practical pathways available to community pharmacists who want to build their menopause expertise, with a strong consensus around The Menopause Society as a foundational starting point, offering position statements, continuing education, an annual meeting boot camp, and a certification pathway open to pharmacists, nurse practitioners, physical therapists, mental health counselors, and physicians.

Learn how pharmacists secure access to new therapies with co-pay cards, BlinkRx pricing, and prior authorization tips that cut delays.

Pharmacists step up in menopause care by educating patients, personalizing treatment for hot flashes, and closing follow-up gaps with new FDA-approved options.